<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04220294</url>
  </required_header>
  <id_info>
    <org_study_id>0621-19-RMB</org_study_id>
    <nct_id>NCT04220294</nct_id>
  </id_info>
  <brief_title>Subcutaneous Continuous Versus Interrupted Sutures During Cesarean Section.</brief_title>
  <official_title>Surgical Site Infection Rate After Subcutaneous Continuous Versus Interrupted Sutures During Cesarean Section.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparison of the rate of surgical site infections after cesarean section depending on the
      type of suture used for subcutaneous closure-continuous versus interrupted.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients at term that are candidates for elective cesarean section or patients undergoing
      emergent cesarean section will receive an explanation regarding the study and sign informed
      consent. Patients will then be divided randomly to one of 2 treatment groups based on the
      type of subcutaneous tissue closure:

        1. Interrupted sutures.

        2. Continuous sutures. Information regarding medical and obstetric history will be
           collected for each patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical site infection rate.</measure>
    <time_frame>From admission up to 2 weeks postpartum.</time_frame>
    <description>Surgical site infection rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fever postpartum.</measure>
    <time_frame>From admission up to 2 weeks postpartum.</time_frame>
    <description>The rate of fever over 38 degrees Celsius postpartum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for antibiotics.</measure>
    <time_frame>From admission up to 2 weeks postpartum.</time_frame>
    <description>The rate of antibiotic use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization length.</measure>
    <time_frame>From admission up to 2 weeks postpartum.</time_frame>
    <description>The length of hospitalization postpartum.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1450</enrollment>
  <condition>Suture Line Infection</condition>
  <arm_group>
    <arm_group_label>Interrupted sutures</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous tissue closure by interrupted sutures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous sutures</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous tissue closure by continuous sutures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Subcutaneous tissue closure</intervention_name>
    <description>Subcutaneous tissue closure with 2-0 vicryl suture.</description>
    <arm_group_label>Continuous sutures</arm_group_label>
    <arm_group_label>Interrupted sutures</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women undergoing elective cesarean section.

          -  Pregnant women undergoing emergent cesarean section.

        Exclusion Criteria:

          -  Fever prior to surgery.

          -  Antibiotic use prior to surgery.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roy Lauterbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rambam Healthcare Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roy Lauterbach, MD</last_name>
    <phone>+972-529432416</phone>
    <email>r_lauterbach@rambam.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rambam healthcare campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roy Lauterbach, MD</last_name>
      <phone>+972-52-9432416</phone>
      <email>r_lauterbach@rambam.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 5, 2020</study_first_submitted>
  <study_first_submitted_qc>January 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2020</study_first_posted>
  <last_update_submitted>April 5, 2020</last_update_submitted>
  <last_update_submitted_qc>April 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rambam Health Care Campus</investigator_affiliation>
    <investigator_full_name>ROY LAUTERBACH MD</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

